[ACCESSWIRE]
LONDON, UK / ACCESSWIRE / July 15, 2016 / Active Wall St. announces the list of stocks for today's coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers - Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. See our complete notes on Ionis Pharma at:
http://www.activewallst.com/registration-3/?symbol=IONS
Today, AWS is promoting its equity coverage. Get all of our research notes free by signing up to http://www.activewallst.com/register/.
The Drug Manufacturers industry is expected to see positive growth in the next few years despite rising drug prices, health care policies, and fluctuating economic conditions. Let us see how this is affecting some of the big names in the industry. Register with us now for your free membership and more at: http://www.activewallst.com/register/.
Active Wall St. takes a brief technical look at how each of the companies mentioned above have fared over the last few trading sessions.
Ionis Pharmaceuticals Inc. (NASDAQ: IONS)
On Thursday, shares in Carlsbad, California headquartered RNA-targeted drug discovery and development company, Ionis Pharmaceuticals Inc., recorded a trading volume of 2.32 million shares. The stock ended the day at $24.52, which was a slight correction of 0.65%. The Company's shares have gained 9.71% in the last one month. The stock is trading below its 50-day moving average by 8.22%. Furthermore, shares of Ionis Pharmaceuticals, which focuses on developing drugs for patients with severe and rare diseases, have a Relative Strength Index (RSI) of 47.59.
On July 07, 2016, Ionis Pharmaceuticals announced positive results from two ongoing trials with IONIS-TTRRx. New data from the ongoing open-label extension study of IONIS-TTRRx in patients with familial amyloid polyneuropathy showed that both wild-type and mutant TTR levels were substantially reduced and that the reductions observed were approximately equal in magnitude regardless of the presence or location of the mutation.
Depomed Inc. (NASDAQ: DEPO)
Newark, California headquartered specialty pharmaceutical company, Depomed Inc.'s stock finished yesterday's session 1.99% higher at $18.92 and with a total volume of 720,680 shares traded. The Company's shares have advanced 16.65% over the previous three months and 4.36% on an YTD basis. The stock is trading above its 200-day moving average by 7.64%. Furthermore, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the U.S., have an RSI of 47.36.
On June 24, 2016, Depomed announced that, in response to a second record date request by Starboard Value L.P., it has set a record date of August 19, 2016 to determine shareholders entitled to call a special meeting of shareholders. Depomed today also announced its proposal to hold a special meeting called by its Board on October 28, 2016, that is intended to occur after resolution of the Company's ongoing NUCYNTA® patent litigation, which is expected no later than September 30, 2016.The complimentary note on DEPO can be accessed at: http://www.activewallst.com/registration-3/?symbol=DEPO.
Amarin Corp. PLC (NASDAQ: AMRN)
At the closing bell on Thursday, shares in Dublin, Ireland-based biopharmaceutical company, Amarin Corp. PLC, climbed 0.45%, ending the day at $2.25. The stock recorded a trading volume of 783,180 shares. The Company's shares have advanced 6.13% in the last one month, 27.84% in the previous three months and 19.05% since the start of this year. The stock is trading 13.57% above its 50-day moving average and 25.07% above its 200-day moving average. Moreover, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the U.S., have an RSI of 66.77.
On June 11, 2016 Amarin Corp. announced additional data on Vascepa (icosapent ethyl) at the annual meeting of the American Diabetes Association supporting its efficacy in reducing concentrations of potentially atherogenic lipoproteins in patients with Type 2 diabetes and persistent high triglyceride levels despite statin therapy. Register for free and access the note on AMRN at: http://www.activewallst.com/registration-3/?symbol=AMRN.
United Therapeutics Corp. (NASDAQ: UTHR)
Silver Spring, Maryland headquartered biotechnology company, United Therapeutics Corp.’s stock ended the day 0.89% higher at $110.21 and with a total volume of 430,793 shares traded. The Company's shares have gained 2.75% in the last month. The stock is trading 0.13% below its 50-day moving average. Additionally, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases globally, have an RSI of 53.50.
United Therapeutics Corp. is expected to announce second quarter financial results estimates on July 21, 2016. In Its latest earnings announced in April 28, 2016, it posted earnings per share at $4.84 which topped consensus of $3.21. Revenue came in at 369 million versus consensus estimate of 397.42 million. UTHR free note is just a click away at: http://www.activewallst.com/registration-3/?symbol=UTHR.
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
AWS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active Wall Street
